Hiroshi Ueoka

Yamaguchi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice.

Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice.

Journal: Acta medica Okayama

Published: February 27, 2023

Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion.

Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion.

Journal: Clinical and experimental immunology

Published: June 13, 2017

Survival from an Acute Exacerbation of Idiopathic Pulmonary Fibrosis with or without Direct Hemoperfusion with a Polymyxin B-immobilized Fiber Column: A Retrospective Analysis.

Survival from an Acute Exacerbation of Idiopathic Pulmonary Fibrosis with or without Direct Hemoperfusion with a Polymyxin B-immobilized Fiber Column: A Retrospective Analysis.

Journal: Internal medicine (Tokyo, Japan)

Published: December 17, 2016

A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.

A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.

Journal: Cancer chemotherapy and pharmacology

Published: June 16, 2016

Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.

Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.

Journal: Journal of immunological methods

Published: September 01, 2015

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 20, 2015

A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.

A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.

Journal: Chest

Published: December 03, 2014

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 19, 2014

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 07, 2014

Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.

Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.

Journal: Acta medica Okayama

Published: June 26, 2012

Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Journal: Cytokine

Published: April 05, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026